Silas Inman

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com

Articles

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma

April 25th 2022

The novel allogeneic CAR-engineered natural killer cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia and non-Hodgkin lymphoma.

Biomarkers Allow for Tailoring TNBC Treatments

March 5th 2022

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.

Brain Metastases Are Now More Treatable in HER2+ Metastatic Breast Cancer

March 5th 2022

The treatment of patients with HER2-positive metastatic breast cancer can now be tailored based on the presence of active central nervous system disease, due to substantial advances made in the past few years into small molecule inhibitors and macromolecule biologics.

Real-World Data Describe Eribulin Efficacy After Novel Agents for MBC

March 4th 2022

Treatment with eribulin elicited an estimated 2-year overall survival rate of 53.6% for patients with metastatic breast cancer previously treated with atezolizumab or sacituzumab govitecan, according to real-world findings.

FDA Grants Orphan Drug Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers

February 15th 2022

The FDA has granted an orphan drug designation to the off-the-shelf natural killer cell therapy CYNK-101 as a potential treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers

January 18th 2022

The FDA has granted a fast track designation to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Real-World Evidence Supports Axi-Cel in Previously Excluded LBCL Populations

December 13th 2021

Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma; however, adverse events were more common in some of these populations and ECOG performance status ≥2 was associated with worse outcomes and more adverse events, according to a large real-world study presented at the 2021 ASH Annual Meeting.

Daratumumab/IRd Quadruplet Is Safe and Effective as Induction, Consolidation for Standard-Risk Myeloma

December 12th 2021

Extended induction and consolidation therapy with daratumumab plus ixazomib, lenalidomide, and dexamethasone led to deepening rates of minimal residual disease for patients with standard-risk, transplant-eligible newly diagnosed multiple myeloma.

Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

December 11th 2021

The combination of tafasitamab and lenalidomide prolonged median overall survival compared with other standard options for autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

Less-Toxic Ixazomib/Daratumumab Combo Attempted for Intermediate-Fit, Non-Transplant Eligible Newly Diagnosed Multiple Myeloma

December 11th 2021

The combination of ixazomib, daratumumab, and low-dose dexamethasone elicited an objective response rate of 71% in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

Pamrevlumab May Address Unmet Need for Locally Advanced Pancreatic Cancer

February 17th 2021

February 17, 2021 – Pamrevlumab, a first-in-class inhibitor of connective tissue growth factor activity, is being evaluated in combination with gemcitabine and nab-paclitaxel (Abraxane) in a phase 3 trial for patients with unresectable locally advanced pancreatic cancer, a population in need of new options.

Gottlieb Addresses Coronavirus, Innovation in Keynote Address

March 8th 2020

The novel coronavirus spreading across the world represents a distinct challenge for all physicians, especially oncologists who commonly treat patients who have compromised immune systems.

Gene Profiling Essential Tool for Treatment Tailoring

March 7th 2020

Gene profiling assays can accurately and reproducibly assist decision making for patients with hormone receptor-positive breast cancer, with the ultimate goal of improving outcomes or avoiding toxicity.

Updated bb21217 Data Continue to Impress in Multiple Myeloma

December 11th 2019

The CAR T cell therapy bb21217 demonstrated high very good partial response or better rates in patients with heavily pretreated relapsed/refractory multiple myeloma.

Navitoclax Overcomes Ruxolitinib Resistance for Myelofibrosis

December 10th 2019

Navitoclax plus ruxolitinib (Jakafi) showed clinically meaningful spleen responses and improvements in symptoms for patients with primary or secondary myelofibrosis, following the development of resistance to frontline ruxolitinib.

Maintenance CC-486 Improves Survival for Older Patients With AML

December 10th 2019

Maintenance treatment with CC-486, an oral formulation of azacitidine, extended median overall survival by 9.9 months compared with placebo for older patients with acute myeloid leukemia in first remission.

KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned

December 10th 2019

Treatment with the anti-CD19 CAR T-cell therapy KTE-X19 elicited a complete remission rate of 67% and an objective response rate of 93% for patients with relapsed/refractory mantle cell lymphoma.

CPI-0610 Shows Strong Efficacy Signals for Advanced Myelofibrosis

December 10th 2019

CPI-0610 showed promising spleen volume responses and a meaningful reduction in total symptom score as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis.

Zanubrutinib Effective in CLL/SLL, Regardless of Del(17p) Status

December 9th 2019

The BTK inhibitor zanubrutinib continues to demonstrate high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of the presence of high-risk cytogenetics.

LOXO-305 Is Highly Effective in Heavily Pretreated B-cell Malignancies

December 9th 2019

More than half of patients with heavily pretreated B-cell malignancies responded to the noncovalent BTK inhibitor LOXO-305, including those with resistance or intolerance to other BTK inhibitors or BCL2 inhibitors.